Day One Biopharmaceutical (NASDAQ:DAWN) just reported results for the second quarter of 2024.
- Day One Biopharmaceutical reported earnings per share of -5 cents. This was above the analyst estimate for EPS of -62 cents.
- The company reported revenue of $8.19 million.
- This was 703.14% better than the analyst estimate for revenue of $1.02 million.